• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Regulatory Updates for Intravascular Catheters in September 2021

Regulatory Updates for Intravascular Catheters in September 2021

Monday, 25 October 2021 / Published in Medical Device, News, NMPA Registration in China

Regulatory Updates for Intravascular Catheters in September 2021

On September 7, 2021, the NMPA (National Medical Products Administration) announced (No.68-2021) the technical review guideline for the clinical evaluation of intravascular catheter products in comparison with its predicate devices.

Highlights

  • Predicate devices must be sold in the market already, and should be similiar to the applicant product in terms of intended use, technical characteristics and biological characteristics.
  • The guideline’s objective is to ensure the clinical data of the predicate device is being used reasonably as supporting evidence to prove the product is safe and effective for clinical use.
  • Basic requirements of the clinical evaluation in comparison with predicate devices including but not limited to the following:
    • Anatomic sites for catheters should be described and compared in detail.
    • Product designs should be compared in detail because the outcome might be different in terms of the function. For example, a specially designed head-end configuration is used to reduce vascular damage.
    • Comparison of the basic structure in terms of number and size of different cavities, the types of joint, the position and number of holes in the end of the catheters and the coating.
    • Production process and manufacturing materials: Raw materials that may have direct or indirect contact with the human body should be compared.
    • Performance Requirements: Based on the product category, intravascular catheters should comply with the mandatory industrial standard YY0285, and take the corresponding technical requirements of the product design features as reference.
  • According to Order 739, clinical trials can be exempted if the safety and effectiveness of medical devices can be proven by other non-clinical evaluation studies such as existing clinical data of predicate devices in the market, clinical evaluation, etc.

Read our blog post about the clinical trial exemption list for medical devices and IVD reagents recently published by the NMPA in accordance with Order 47 and Order 48 respectively.

By Judith Sun and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: intravascular catheters, predicate devices

What you can read next

New Approval Process for Medical Device Clinical Trials
NMPA UDI Database Officially Open to Public
NMPA Implements the eCTD of Drug Application

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP